CN1254237C - 透明水性麻醉组合物 - Google Patents

透明水性麻醉组合物 Download PDF

Info

Publication number
CN1254237C
CN1254237C CNB008198292A CN00819829A CN1254237C CN 1254237 C CN1254237 C CN 1254237C CN B008198292 A CNB008198292 A CN B008198292A CN 00819829 A CN00819829 A CN 00819829A CN 1254237 C CN1254237 C CN 1254237C
Authority
CN
China
Prior art keywords
propofol
autoclaving
pharmaceutical composition
clear aqueous
aqueous pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008198292A
Other languages
English (en)
Chinese (zh)
Other versions
CN1454085A (zh
Inventor
S·佩
S·里范卡
S·科查雷卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bharat Serums and Vaccines Ltd
Original Assignee
Bharat Serums and Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums and Vaccines Ltd filed Critical Bharat Serums and Vaccines Ltd
Publication of CN1454085A publication Critical patent/CN1454085A/zh
Application granted granted Critical
Publication of CN1254237C publication Critical patent/CN1254237C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB008198292A 2000-06-21 2000-12-14 透明水性麻醉组合物 Expired - Fee Related CN1254237C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN573/MUM/2000 2000-06-21
IN573MU2000 IN187686B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2000-06-21 2000-06-21

Publications (2)

Publication Number Publication Date
CN1454085A CN1454085A (zh) 2003-11-05
CN1254237C true CN1254237C (zh) 2006-05-03

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008198292A Expired - Fee Related CN1254237C (zh) 2000-06-21 2000-12-14 透明水性麻醉组合物

Country Status (26)

Country Link
US (1) US7138387B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1299095B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4907833B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100810066B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1254237C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2002002674A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE267592T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU3597201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG107463A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0017268A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2414064C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60011149T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1299095T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA005589B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2222271T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0301646A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL153387A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN187686B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA02012611A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20025999L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ523643A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL359624A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1299095E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001097796A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU2703A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200300336B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
ATE430571T1 (de) * 2001-12-28 2009-05-15 Eisai Corp North America Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol- verbindungen
DE60305438T2 (de) * 2002-02-01 2006-12-21 Shimoda Biotech (Pty.) Ltd., Mill Park Lyophilisierte pharmazeutische zusammensetzung von propofol
CN100438861C (zh) * 2002-07-29 2008-12-03 变换药品公司 含水2,6-二异丙基苯酚药物组合物
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
WO2005067905A1 (ja) * 2004-01-14 2005-07-28 Otsuka Pharmaceutical Factory, Inc. プロポフォール含有脂肪乳剤
MX2007002941A (es) * 2004-09-13 2007-05-24 Bharat Serums & Vaccines Ltd Composiciones de emulsion estables para administracion intravenosa que tienen eficacia libre de conservadores.
US20090203794A1 (en) * 2005-08-12 2009-08-13 Gautam Vinod Daftary Aqueous Anaesthetic Composition Comprising Propofol
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
US8663874B2 (en) * 2008-03-11 2014-03-04 3M Innovative Properties Company Hardcoat composition
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
WO2011011167A2 (en) 2009-07-21 2011-01-27 3M Innovative Properties Company Curable composition, method of coating a phototool, and coated phototool
CN102549042B (zh) 2009-09-16 2015-01-28 3M创新有限公司 氟化涂料和用其制作的底片
US8748060B2 (en) 2009-09-16 2014-06-10 3M Innovative Properties Company Fluorinated coating and phototools made therewith
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP3407875A4 (en) * 2016-01-29 2019-09-04 Cuda Anesthetics, LLC AQUEOUS PHARMACEUTICAL FORMULATION WITH PROPOFOL
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
DE60011149T2 (de) 2005-07-07
HUP0301646A2 (hu) 2003-09-29
HUP0301646A3 (en) 2005-06-28
IL153387A0 (en) 2003-07-06
US7138387B2 (en) 2006-11-21
JP2003535893A (ja) 2003-12-02
BG107463A (en) 2003-11-28
ZA200300336B (en) 2004-04-08
DK1299095T3 (da) 2004-10-11
NO20025999D0 (no) 2002-12-13
WO2001097796A1 (en) 2001-12-27
MXPA02012611A (es) 2004-07-30
US20040014718A1 (en) 2004-01-22
KR100810066B1 (ko) 2008-03-05
CN1454085A (zh) 2003-11-05
AU2001235972B2 (en) 2005-07-21
AP2002002674A0 (en) 2002-12-31
CA2414064C (en) 2013-01-08
EA200300047A1 (ru) 2003-06-26
JP4907833B2 (ja) 2012-04-04
ES2222271T3 (es) 2005-02-01
AU3597201A (en) 2002-01-02
EP1299095B1 (en) 2004-05-26
PL359624A1 (en) 2004-08-23
IN187686B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-06-08
NO20025999L (no) 2002-12-13
CA2414064A1 (en) 2001-12-27
EA005589B1 (ru) 2005-04-28
DE60011149D1 (de) 2004-07-01
PT1299095E (pt) 2004-10-29
NZ523643A (en) 2004-05-28
ATE267592T1 (de) 2004-06-15
YU2703A (sh) 2006-03-03
BR0017268A (pt) 2003-05-27
KR20030023875A (ko) 2003-03-20
EP1299095A1 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
CN1254237C (zh) 透明水性麻醉组合物
CN100346784C (zh) 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途
CN1232244C (zh) 稳定的非水性单相粘性载体及采用该载体的制剂
CN1222321C (zh) 含有环糊精和紫杉醇类物质的药物组合物
CN1108152C (zh) 口服雷怕霉素配方
CN1028961C (zh) 制备药用溶液的方法
CN101065128A (zh) 液体生物活性剂的固体制剂
CN1010279B (zh) 含有斯波胍灵活性成分的注射用药物组合物的制备方法
CN1090509A (zh) 药用组合物
CN1416337A (zh) 麻醉制剂
CN1761485A (zh) 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂
CN1283235C (zh) 清澈稳定的丙泊酚组合物
CN1843327A (zh) 一种稳定的含有多种维生素的冻干制剂及其制备方法
CN1248680C (zh) 紫杉醇的可注射组合物
CN101066260A (zh) 一种辅酶q10乳剂及其冻干乳剂及制备方法
CN1265838C (zh) 用于小动物的可注射兽医合成物
US8765190B2 (en) Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles
CN1792362A (zh) 阿比朵尔及其盐的静脉给药制剂及制备方法
CN1694713A (zh) oxazaphosphorine和美司钠的液态稳定组合物
CN1263736C (zh) 四水合n-[邻-(对-三甲基乙酰氧基苯磺酰胺基)苯甲酰基]甘氨酸单钠盐的溶液及其药品
CN1213756C (zh) 治疗寄生虫病的兽医组合物
CN1183908C (zh) 一种尼莫地平的注射用药物组合物及其制备方法
CN1404397A (zh) 杀体内寄生虫组合物
CN1784237A (zh) 含有甲基维生素b12的冻干制剂及其制备方法
CN1927206A (zh) 氯诺昔康注射用组合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060503

Termination date: 20161214